Summary by Moomoo AI
On May 14, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported the entry into a Material Definitive Agreement with an institutional investor for a private placement. The agreement includes the sale of 1,700,000 shares of common stock, 325,317 pre-funded warrants, and series A and B warrants to purchase up to 2,025,317 shares each, generating gross proceeds of approximately $8.0 million. The pre-funded warrants and common warrants are immediately exercisable, with the series A warrants expiring five and a half years post-issuance and the series B warrants expiring 18 months post-issuance. The company also entered into a Registration Rights Agreement, obligating it to file a registration statement with the SEC by May 29, 2024, for the resale of the shares. Additionally, T2 Biosystems agreed to pay H...Show More